News & Updates
Showing Multidisciplinary articles
Showing
Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC
Nadofaragene firadenovec-vncg helps preserve the bladder in patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) at 5 years, with an acceptable safety profile, as shown in a phase III trial.
SABR yields better survival, tumour control in oligometastatic HCC
Treatment with stereotactic ablative radiotherapy (SABR) results in excellent local tumour control and improves survival among patients with oligometastatic hepatocellular carcinoma (HCC), with no serious adverse effects, reports a study.
9-month, oral modified treatment regimens make the grade in drug-resistant TB
Nine-month, fully oral modified short treatment regimens (mSTRs) consisting of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine or delamanid appear to yield high treatment success and good safety results in the treatment of patients with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis (TB), according to a study.
Bladder cancer survivors who do not smoke enjoy better life quality
Among patients with bladder cancer (BC), those who do not smoke appear to have better longitudinal health-related quality of life (HRQoL) measures, particularly in the domains of physical function, emotional function, and fatigue, according to a recent study.
Liver stiffness predicts decompensation, mortality in ALD patients
Clinicians may use liver stiffness measurement (LSM) by transient elastography (TE) to accurately predict decompensation and all-cause mortality in patients with compensated alcohol-related liver disease (ALD), suggests a study.
Low-intensity shockwave therapy plus tadalafil improves erectile function in men with ED
Combination treatment with 12 sessions of low-intensity shockwave therapy (LiST) three times weekly and daily tadalafil for 4 weeks results in a 2-point difference in the International Index of Erectile Function–Erectile Function domain (IIEF-EF) compared with sham therapy plus tadalafil in patients with severe vasculogenic erectile dysfunction (ED) after 1 and 3 months of treatment completion.
NOTUS boosts dupilumab role for COPD, type 2 inflammation
The phase III NOTUS trial further validates the potential of the monoclonal antibody dupilumab in reducing exacerbations and improving lung function and quality of life (QoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation.